Medtronic plans to spin out its diabetes business due to increased competition in the market. Other companies have already received FDA authorization for insulin pumps and CGMs for Type 2 diabetes, challenging Medtronic’s position. Insulet leads the U.S. market for insulin pumps and is expanding globally, while Tandem Diabetes Care, Beta Bionics, Sequel MedTech, and […]